GAITHERSBURG, Md. and SHANGHAI, May 1, 2023
/PRNewswire/ -- I-Mab ("I-Mab" or the "Company") (Nasdaq: IMAB), a
clinical-stage biopharmaceutical company committed to the
discovery, development, and commercialization of novel biologics,
today announced that it has filed its annual report on Form 20-F
for the year ended December 31, 2022
with the U.S. Securities and Exchange Commission ("SEC") on
May 1, 2023.
The annual report is available on the Company's investor
relations website at ir.i-mabbiopharma.com and on the
SEC's website at www.sec.gov. The Company will provide hard
copies of the annual report, free of charge, to its shareholders
and ADS holders upon written request. Requests should be directed
to Investor Relations, I-Mab, 55th Floor, New Bund Center, 555 West
Haiyang Road, Pudong District, Shanghai, 200124, People's Republic of China.
About I-Mab
I-Mab (Nasdaq: IMAB) is a dynamic, global biotech company
exclusively focused on discovery, development and soon,
commercialization of novel or highly differentiated biologics in
the therapeutic areas of immuno-oncology and autoimmune diseases.
The Company's mission is to bring transformational medicines to
patients around the world through innovation. I-Mab's innovative
pipeline of more than 10 clinical and pre-clinical stage drug
candidates is driven by the Company's Fast-to-Proof-of-Concept and
Fast-to-Market development strategies through internal R&D and
global partnerships and commercial partnerships. I-Mab as
established its global footprint in Shanghai, Beijing, Hangzhou, Lishui and Hong Kong in China, and Maryland and San
Diego in the United States.
For more information, please visit
http://www.i-mabbiopharma.com and follow I-Mab on
LinkedIn, Twitter, and WeChat.
For more information, please contact:
I-Mab Contacts
Richard Yeh
Chief Operating
Officer, interim Chief Financial Officer
IR@i-mabbiopharma.com
|
Gigi Feng
Chief Communications
Officer
PR@i-mabbiopharma.com
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/i-mab-filed-2022-annual-report-on-form-20-f-301811823.html
SOURCE I-Mab